- Home
- PLMR vs NAMS Comparison
PLMR vs NAMS Comparison
Compare PLMR & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLMR | NAMS |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.8B |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PLMR | NAMS |
|---|---|---|
| Price | $135.73 | $20.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 16 |
| Target Price | ★ $159.17 | $49.96 |
| AVG Volume (30 Days) | 214.4K | ★ 1.3M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | ★ 60.04 | 32.81 |
| EPS | ★ 3.51 | N/A |
| Revenue | ★ $875,967,000.00 | $22,503,000.00 |
| Revenue This Year | $35.94 | $30.15 |
| Revenue Next Year | $24.29 | $384.12 |
| P/E Ratio | $38.37 | ★ N/A |
| Revenue Growth | ★ 58.16 | N/A |
| 52 Week Low | $100.81 | $19.13 |
| 52 Week High | $147.62 | $42.21 |
Technical Indicators
Market Signals| Indicator | PLMR | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 52.23 | 43.01 |
| Support Level | $117.17 | $19.58 |
| Resistance Level | $144.73 | $22.29 |
| Average True Range (ATR) | 4.11 | 1.09 |
| MACD | 0.07 | 0.07 |
| Stochastic Oscillator | 42.07 | 46.52 |
Price Performance
Historical ComparisonAbout PLMR Palomar Holdings Inc.
Palomar Holdings Inc that provides property and casualty insurance products to individuals and businesses. It provides insurance products serving five categories: Earthquake, Inland Marine and Other Property, Casualty, Fronting, and Crop. Company distribute products through multiple channels, including retail agents, program administrators, wholesale brokers, and partnerships with other insurance companies. The company's Earthquake product generate high premium.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.